(Q83945182)
Statements
Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years (English)
Steven Black
Leonard R Friedland
Anne Schuind
Barbara Howe
GlaxoSmithKline DTaP-IPV Vaccine Study Group
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
2 references
1 reference
1 reference
1 reference